© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 5, 284-290,
March 6, 1996
© 1996 Oxford University Press
Estrogen Receptor Variants in Normal Human Mammary Tissue
Department of Biochemistry and Molecular Biology, University of Manitoba Winnipeg, Canada
Department of Pathology, University of Manitoba Winnipeg, Canada
Correspondence to: E. R Leygue, Ph.D., Department of Biochemistry and Molecular Biology. University of Manitoba, Winnipeg. Manitoba, Canada R3E OW3.
BACKGROUND: Several estrogen receptor (ER) variant messenger RNAs (mRNAs) have been identified previously in human breast cancer biopsy samples and cell lines. The relative levels of certain ER variant mRNAs have been observed to increase with breast tumor progression. In vitro assays of the function of polypeptides encoded by some of these variant mRNAs have led to speculation that ER variants may be involved in the progression from hormone dependence to independence in breast cancer.
PURPOSE: We set out to establish if ER variant mRNAs are present in normal human breast tissues and, if so, to compare levels of these variants between normal and neoplastic human breast tissues.
METHODS: Four human breast tissue samples from reduction mammoplasties and five samples from tissue adjacent to breast tumors were analyzed. The tissue samples were confirmed to be normal (i.e., not malignant) by histopathologic analysis. RNA was extracted immediately from adjacent frozen sections. Human breast tumor specimens originally resected from 19 patients were acquired from a tumor bank and processed in the same way as the normal tissue samples. The RNAs were then reverse transcribed and subsequently amplified with the use of the polymerase chain reaction (PCR). PCR primer sets were designed to detect several different exon-deleted ER variants and a truncated ER variant (i.e., clone 4). A semiquantitative PCR-based method was used to determine the relative expression of exon 5- and exon 7-deleted variants to wild-type ER mRNAs in the nine normal breast tissues and in 19 ER-positive breast tumor tissues. The Mann-Whitney rank sum test (two-sided) was used to determine P values.
RESULTS: ER variant mRNAs corresponding to the clone 4 ER truncated variant and to variants deleted in either exon 2, exon 3, exons 2–3, exon 5, or exon 7 were detected in all normal samples. The results were confirmed by restriction enzyme analyses and sequencing of the PCR products. The expression of exon 5-deleted ER variant relative to the wild-type ER mRNA was significantly lower (P<.001) in normal tissue than in tumor tissue. A similar trend was noted for expression of the exon 7-deleted ER variant mRNA; however, the difference did not achieve statistical significance (P = .476).
CONCLUSION: Several ER variant mRNAs are present in normal human breast tissue, but the level of expression of some of these variants may be lower in normal tissue than in tumor tissue.
IMPLICATION: These data suggest that the mechanisms generating ER variant mRNAs exist in normal breast tissue and may be deregulated in breast cancer tissues. Further investigation of the role of variant ER expression in development and progression of human breast cancer appears warranted. [J Natl Cancer Inst 1996;88:284–90]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. O. Barnes, M. Parisien, L. C. Murphy, and P. H. Watson Influence of Evolution in Tumor Biobanking on the Interpretation of Translational Research Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3344 - 3350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Miksicek, Y. Myal, P. H. Watson, C. Walker, L. C. Murphy, and E. Leygue Identification of a Novel Breast- and Salivary Gland-specific, Mucin-like Gene Strongly Expressed in Normal and Tumor Human Mammary Epithelium Cancer Res., May 1, 2002; 62(10): 2736 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Murphy, S. L. R. Simon, A. Parkes, E. Leygue, H. Dotzlaw, L. Snell, S. Troup, A. Adeyinka, and P. H. Watson Altered Expression of Estrogen Receptor Coregulators during Human Breast Tumorigenesis Cancer Res., November 1, 2000; 60(22): 6266 - 6271. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. R. Simon, A. Parkes, E. Leygue, H. Dotzlaw, L. Snell, S. Troup, A. Adeyinka, P. H. Watson, and L. C. Murphy Expression of a Repressor of Estrogen Receptor Activity in Human Breast Tumors: Relationship to Some Known Prognostic Markers Cancer Res., June 1, 2000; 60(11): 2796 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-M. Lau, M. LaSpina, J. Long, and S.-M. Ho Expression of Estrogen Receptor (ER)-{{alpha}} and ER-{beta} in Normal and Malignant Prostatic Epithelial Cells: Regulation by Methylation and Involvement in Growth Regulation Cancer Res., June 1, 2000; 60(12): 3175 - 3182. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Speirs, I. P. Adams, D. S. Walton, and S. L. Atkin Identification of Wild-Type and Exon 5 Deletion Variants of Estrogen Receptor {beta} in Normal Human Mammary Gland J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1601 - 1605. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. J. van Dijk, A. A. M. Hart, and L. J. v.'t Veer Differences in Estrogen Receptor {{alpha}} Variant Messenger RNAs between Normal Human Breast Tissue and Primary Breast Carcinomas Cancer Res., February 1, 2000; 60(3): 530 - 533. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Al-Haddad, Z. Zhang, E. Leygue, L. Snell, A. Huang, Y. Niu, T. Hiller-Hitchcock, K. Hole, L. C. Murphy, and P. H. Watson Psoriasin (S100A7) Expression and Invasive Breast Cancer Am. J. Pathol., December 1, 1999; 155(6): 2057 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Leygue, H. Dotzlaw, P. H. Watson, and L. C. Murphy Expression of the Steroid Receptor RNA Activator in Human Breast Tumors Cancer Res., September 1, 1999; 59(17): 4190 - 4193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scorilas, E. P. Diamandis, M. A. Levesque, A. Papanastasiou-Diamandi, M. J. Khosravi, M. Giai, R. Ponzone, R. Roagna, P. Sismondi, and C. Lopez-Otin Immunoenzymatically Determined Pepsinogen C Concentration in Breast Tumor Cytosols: An Independent Favorable Prognostic Factor in Node-positive Patients Clin. Cancer Res., July 1, 1999; 5(7): 1778 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Hodges, J. K. Richer, K. B. Horwitz, and L. D. Horwitz Variant Estrogen and Progesterone Receptor Messages in Human Vascular Smooth Muscle Circulation, May 25, 1999; 99(20): 2688 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Balleine, S. M. N. Hunt, and C. L. Clarke Coexpression of Alternatively Spliced Estrogen and Progesterone Receptor Transcripts in Human Breast Cancer J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1370 - 1377. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Budhram-Mahadeo, M. Parker, and D. S. Latchman POU Transcription Factors Brn-3a and Brn-3b Interact with the Estrogen Receptor and Differentially Regulate Transcriptional Activity via an Estrogen Response Element Mol. Cell. Biol., February 1, 1998; 18(2): 1029 - 1041. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Erenburg, B. Schachter, R. M. y Lopez, and L. Ossowski Loss of an Estrogen Receptor Isoform (ER{alpha}{Delta}3) in Breast Cancer and the Consequences of Its Reexpression: Interference with Estrogen-Stimulated Properties of Malignant Transformation Mol. Endocrinol., December 1, 1997; 11(13): 2004 - 2015. [Abstract] [Full Text] [PDF]
|
|